Technical Analysis for ARRY - Array BioPharma Inc.
|Grade||Last Price||% Change||Price Change|
ARRY closed up 0.92 percent on Friday, March 23, 2018, on 58 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|Weak or Absent||Up||Up||Down|
|See historical ARRY trend table...|
|Date||Alert Name||Type||% Chg|
|Mar 23||50 DMA Support||Bullish||0.00%|
|Mar 23||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||0.00%|
|Mar 23||Stochastic Reached Oversold||Weakness||0.00%|
|Mar 23||Strong but Oversold||Other||0.00%|
|Mar 23||Wide Bands||Range Expansion||0.00%|
|Mar 23||Oversold Stochastic||Weakness||0.00%|
|Mar 22||Lower Bollinger Band Walk||Weakness||0.92%|
|Mar 22||Strong but Oversold||Other||0.92%|
|Mar 22||Outside Day||Range Expansion||0.92%|
|Mar 22||Wide Bands||Range Expansion||0.92%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Its proprietary clinical programs include ARRY-520, a kinesin spindle protein inhibitor, which is in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie2 dual inhibitor that is in Phase 1 clinical trial for the treatment of myelodysplastic syndromes; ARRY-797, a p38 inhibitor, which is in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist that is in Phase 2 clinical trial for asthma. The company's partnered clinical programs comprise drug candidates for the treatment of cancer, including MEK162, an MEK inhibitor in Phase 3 clinical trial; Selumetinib, an MEK inhibitor in Phase 2/pivotal clinical trial; and GDC-0068 AKT inhibitor, LY2606368 Chk-1 inhibitor, and VTX-2337 toll-like receptor in Phase 2 clinical trial. Its partnered clinical programs also include Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 clinical trial; ARRY-543/ASLAN001, a HER2/EGFR inhibitor for gastric cancer in Phase 2 clinical trial; GDC-0575 and GDC-0425 Chk-1 inhibitors for cancer in Phase 1b clinical trial; ARRY-380, an HER2 inhibitor in Phase 1 clinical trial for breast cancer; and GDC-0994 in a Phase 1 dose-escalation study in patients with locally advanced or metastatic solid tumors. The company has collaborations with Amgen Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Eli Lilly and Company; Genentech Inc.; Novartis International Pharmaceutical Ltd.; Oncothyreon Inc.; and VentiRx Pharmaceuticals, Inc. for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ARRY news...
|52 Week High||18.78|
|52 Week Low||6.73|
|200-Day Moving Average||11.7651|
|50-Day Moving Average||16.3542|
|20-Day Moving Average||17.4775|
|10-Day Moving Average||17.027|
|Average True Range||0.752|
|Chandelier Exit (Long, 3 ATRs )||16.524|
|Chandelier Exit (Short, 3 ATRs )||18.336|
|Upper Bollinger Band||18.7426|
|Lower Bollinger Band||16.2124|
|Percent B (%b)||0.11|
|MACD Signal Line||0.2762|
|Market Cap||2.83 Billion|
|Num Shares||171 Million|
|Price-to-Earnings (P/E) Ratio||-22.92|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||17.76|
|Resistance 3 (R3)||17.81||17.43||17.55|
|Resistance 2 (R2)||17.43||17.11||17.41||17.48|
|Resistance 1 (R1)||16.97||16.91||17.20||16.92||17.41|
|Support 1 (S1)||16.13||16.27||16.36||16.08||15.59|
|Support 2 (S2)||15.75||16.07||15.73||15.52|
|Support 3 (S3)||15.29||15.75||15.45|
|Support 4 (S4)||15.24|